Advertisement

Clinical efficacy of bortezomib and lenalidomide in blastic plasmacytoid dendritic cell neoplasm

  • Chunli Yang
  • Chunxi Fu
  • You Feng
  • Sha Zhao
  • Huawei Weng
  • Li Zhang
  • Hongyan Du
  • Liqun ZouEmail author
Letter to the Editor
  • 37 Downloads

Notes

Authors’ contributions

Each author was involved in the writing of the manuscript. All authors approved the final manuscript.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no competing interests.

Informed consent

Informed consent was obtained from the participating patient of the case description.

References

  1. 1.
    Bueno C, Almeida J, Lucio P, Marco J, Garcia R, de Pablos JM, Parreira A, Ramos F, Ruiz-Cabello F, Suarez-Vilela D, San Miguel JF, Orfao A (2004) Incidence and characteristics of CD4(+)/HLA DRhi dendritic cell malignancies. Haematologica 89:58–69Google Scholar
  2. 2.
    Martin-Martin L, Lopez A, Vidriales B et al (2015) Classification and clinical behavior of blastic plasmacytoid dendritic cell neoplasms according to their maturation-associated immunophenotypic profile. Oncotarget 6:19204–19216CrossRefGoogle Scholar
  3. 3.
    Petrella T, Bagot M, Willemze R, Beylot-Barry M, Vergier B, Delaunay M, Meijer CJLM, Courville P, Joly P, Grange F, de Muret A, Machet L, Dompmartin A, Bosq J, Durlach A, Bernard P, Dalac S, Dechelotte P, D’Incan M, Wechsler J, Teitell MA (2005) Blastic NK-cell lymphomas (agranular CD4+CD56+ hematodermic neoplasms). Am J Clin Pathol 123:662–675CrossRefGoogle Scholar
  4. 4.
    Sapienza MR, Fuligni F, Agostinelli C et al (2014) Molecular profiling of blastic plasmacytoid dendritic cell neoplasm reveals a unique pattern and suggests selective sensitivity to NF-kB pathway inhibition. Leukemia 28:1606–1616CrossRefGoogle Scholar
  5. 5.
    Remco Dijkman RVDK (2007) Gene-expression profiling and array-based CGH classify CD4+CD56+hematodermic neoplasm and cutaneous myelomonocytic leukemia as distinct disease entities. Blood 109:1720–1727CrossRefGoogle Scholar
  6. 6.
    Philippe L, Ceroi A, Bôle-Richard E, Jenvrin A, Biichle S, Perrin S, Limat S, Bonnefoy F, Deconinck E, Saas P, Garnache-Ottou F, Angelot-Delettre F (2017) Bortezomib as a new therapeutic approach for blastic plasmacytoid dendritic cell neoplasm. Haematologica 102:1861–1868CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  • Chunli Yang
    • 1
  • Chunxi Fu
    • 1
  • You Feng
    • 1
  • Sha Zhao
    • 2
  • Huawei Weng
    • 3
  • Li Zhang
    • 4
  • Hongyan Du
    • 1
  • Liqun Zou
    • 1
    Email author
  1. 1.Department of Medical Oncology, Cancer Center, West China HospitalSichuan UniversityChengduChina
  2. 2.Department of Pathology, West China HospitalSichuan UniversityChengduChina
  3. 3.Department Medical OncologyXiang’an Hospital of Xiamen UniversityXiamenChina
  4. 4.National Cancer Center/Cancer Hospital & Shenzhen HospitalChinese Academy of Medical Sciences and Peking Union Medical CollegeShenzhenChina

Personalised recommendations